Essential and Evolving Strategies for Recognizing and Addressing Agitation Associated with Dementia due to Alzheimer’s Disease: Collaborative Care with Patients and Care Partners

Thursday, December 7, 2023

10:30 AM – 11:30 AM USA

Presenter(s)

Kevin N. Williams, MS, MPAS, PA-C

CEO and Lead Clinician
OnPoint Behavioral Health
Ithaca College
Tampa, Florida
Kevin N. Williams, MS, MPAS, PA-C

CEO and Lead Clinician
OnPoint Behavioral Health
Ithaca College
Tampa, Florida
GG

George T. Grossberg, MD

Professor, Director, Division of Geriatric Psychiatry, Department of Psychiatry & Behavioral Neuroscience ,St. Louis University School of Medicine, St. Louis, Missouri
St Louis University School of Medicine
St Louis University
st louis, Missouri
GG

George T. Grossberg, MD

Professor, Director, Division of Geriatric Psychiatry, Department of Psychiatry & Behavioral Neuroscience ,St. Louis University School of Medicine, St. Louis, Missouri
St Louis University School of Medicine
St Louis University
st louis, Missouri
MM

Marilyn Martin

Caregiver
Self employed
Thousand Palms, California
MM

Marilyn Martin

Caregiver
Self employed
Thousand Palms, California

Disclosure(s):

Kevin N. Williams, MS, MPAS, PA-C: No financial relationships to disclose

Alzheimer's disease is a global healthcare challenge affecting older individuals and is a significant global healthcare challenge. Agitation in dementia due to Alzheimer's disease (AADAD) leads to disease progression, reduced well-being, and increased caregiving emotional, physical and financial burden. Recent advances have brought the first FDA-approved treatment for AADAD, and clinicians, including psychiatry and primary care healthcare professionals, are pivotal in improving patient and caregiver quality of life. This session covers AADAD's impact on patients and families, current treatments, and patient-centered management through shared decision-making.

Supported by an educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

Learning Objectives:

Define agitation and its role in Alzheimer’s dementia, including its precipitating factors, symptoms, diagnostic criteria, potential pathophysiological mechanisms, and the unmet burdens associated with the condition
Assess the utility and limitations of therapies traditionally used to address AADAD
Describe the mechanisms of action, most recent clinical data, and treatment implications associated with current and emerging therapies for AADAD
Implement optimal management strategies for AADAD that incorporate the principles of shared decision-making with clinicians, care partners and personalized, patient-centered care